New York, NY, United States of America

John D Karkas


Average Co-Inventor Count = 3.6

ph-index = 2

Forward Citations = 31(Granted Patents)


Company Filing History:


Years Active: 1988-1997

Loading Chart...
3 patents (USPTO):Explore Patents

Title: John D Karkas: Innovator in Antiviral Research

Introduction

John D Karkas is a notable inventor based in New York, NY (US). He has made significant contributions to the field of antiviral research, particularly in the development of compounds aimed at inhibiting herpes viruses. With a total of 3 patents to his name, Karkas has established himself as a key figure in pharmaceutical innovation.

Latest Patents

Karkas's latest patents include "Prodrugs of herpes TK inhibitors" and "Anti-viral guanine compounds." The first patent describes certain prodrugs that are effective in inhibiting herpes virus thymidine kinase. These compounds are useful in preventing or treating recurrent herpes virus infections, either alone or in combination with other antiviral agents, immunomodulators, antibiotics, or vaccines. The second patent focuses on guanine compounds that exhibit potent antiviral activity against herpes viruses. It details the preparation methods for these compounds and their derivatives, highlighting their potential in treating DNA viral infections.

Career Highlights

John D Karkas is currently associated with Merck & Company, Inc., a leading global healthcare company. His work at Merck has allowed him to contribute to groundbreaking research in antiviral therapies. Karkas's innovative approaches have paved the way for new treatment options for patients suffering from viral infections.

Collaborations

Throughout his career, Karkas has collaborated with esteemed colleagues such as Richard L Tolman and Wallace T Ashton. These collaborations have further enhanced his research and development efforts in the field of antiviral medications.

Conclusion

John D Karkas is a distinguished inventor whose work in antiviral research has led to significant advancements in the treatment of herpes virus infections. His contributions continue to impact the pharmaceutical industry and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…